Organon stock cut their dividend by over 90%. There are lessons here for all income investors. Click here to find out what ...

BofA analyst Jason Gerberry lowered the firm’s price target on Organon (OGN) to $10 from $11 and keeps an Underperform rating ...

Shares of Organon (NYSE:OGN) plunged ~13% in the premarket on Thursday after the company, with its Q1 2025 financials, ...

Shares of Organon & Co. fell to a record low on Thursday after a series of analyst downgrades and price target cuts followed ...

Organon & Co. advanced stock charts by Barron's. View OGN historical stock data and compare to other stocks, and exchanges.

Despite a 4% revenue decline, Organon & Co (OGN) sees promising growth in key segments like Nexplanon and Vtama, while focusing on debt reduction and strategic expansion.

Organon was hurt in Q4/2024 by flat year-over-year sales. The company saw a 37% decline (excluding foreign exchange) in ...

The Jersey City, N.J., pharmaceutical company cut its quarterly dividend to 2 cents a share, down from the prior 28 cents a share. Chief Executive Kevin Ali said the company reset its ...

The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws.

The Jersey City, New Jersey-based company said it had net income of 33 cents per share. Earnings, adjusted for one-time gains and costs, were $1.02 per share. The results topped Wall Street ...

Organon reaffirmed its full-year 2025 revenue guidance of $6.125-6.325 billion, with the midpoint slightly below the consensus estimate of $6.292 billion. The company also expects to generate over ...